NCT03350659View on ClinicalTrials.gov

Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

January 29, 2019

Study Completion Date

March 15, 2019

Conditions
Neurogenic Orthostatic Hypotension
Interventions
DRUG

Midodrine

Midodrine single 5mg/day

DRUG

Atomoxetine

Atomoxetine single 18mg/day

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Kyung Hee University Hospital at Gangdong

OTHER

lead

Seoul National University Hospital

OTHER

NCT03350659 - Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH | Biotech Hunter | Biotech Hunter